Introduction
Amyloidosis is a highly diverse disorder characterized by the progressive deposition of fibrillary proteins in various organs resulting in loss of function and finally organ failure. More than 30 chemically different amyloid fibril proteins have been described, some are more local and others systemic in the organism. 1,2 Among all amyloidoses, the systemic immunoglobulin light chain-derived (AL) amyloidosis (53%) and the systemic transthyretin-derived (ATTR) amyloidosis (42%) are the most prevalent forms with a shift in ageing populations to ATTR. In both, the heart can be affected as main organ and the presence and severity of cardiac involvement vary with the type of amyloidosis.
3 -5 Irrespective of the amyloid class, patients with cardiac amyloidosis usually present with left ventricular (LV) hypertrophy, and symptoms of heart failure such as dyspnoea, peripheral oedema, and palpitations secondary to arrhythmias. 6 -8 Median survival of patients with cardiac amyloidosis and congestive heart failure is significantly reduced as compared to patients lacking severe heart involvement. In principle, survival rates differ substantially within the group of patients with amyloidosis and severe cardiac involvement. 8 Therefore, the identification of patients with cardiac amyloidosis at high risk of death is urgently needed. In principle, immunohistological signs of chronic inflammation in patients with dilated and hypertrophic cardiomyopathy are related to poor outcome in terms of cardiovascular death and need for heart transplantation.
9 -14 The incidence of cardiac inflammation in cardiac amyloidosis and its impact on disease progression and survival are not known. Because of this, we evaluated the influence of endomyocardial biopsy (EMB)-proven intramyocardial inflammation on mortality in patients with cardiac amyloidosis.
Methods
Overall, 277 out of 1542 EMBs were positive for amyloid (17.9%) as determined by the apple-green birefringence under polarized light after Congo red staining. Based on the availability of data on mortality, amyloid type and myocardial inflammation, we included 54 consecutive patients enrolled from four transnational university hospitals (mean age 68.83 ± 9.59 years; 45 men) with cardiac amyloidosis obtained between 2003 and 2015 for prognosis. At least seven biopsies were obtained from the left or right ventricle. Coronary artery disease and other possible causes of LV hypertrophy (hypertension, valvular heart disease) had been excluded by angiography prior to EMB in all patients. We followed up patients from first diagnostic biopsy to as long as 36 months (mean 11.5 ± 12 months) and compared their outcome with or without proof of inflammation on EMB. Typing of amyloidosis was performed immunohistochemically using amyloid type specific antibodies ('amY-kit' from www.amYmed.net), which are directed against the amyloidotic conformational epitopes of amyloid.
15
Myocardial inflammation was immunohistochemically diagnosed by CD3 + lymphocytes/mm 2 (Dako, Glostrup, Denmark), CD11a + /LFA-1 + lymphocytes/mm 2 (Immuno Tools, Friesoythe, Germany), CD11b + /Mac-1 + macrophages/mm 2 (ImmunoTools, Friesoythe, Germany), CD45R0 + (Dako, Glostrup, Denmark), and perforin + cytotoxic cells/mm 2 (BD Bioscience, San Jose, CA, USA). The infiltrating cells were quantified by digital image analysis as described elsewhere. 16 In brief, this technique used colour-coded thresholds for the discrimination between artefacts and heart muscle tissue by choosing multiple representative points within the grabbed images from six randomly selected immunohistochemically stained EMB sections. Images for the quantification of infiltrates were grabbed at ×200 magnification. The calculated objects were related to the unit heart area (mm 2 
Results
In our patient cohort, the overall mortality was 29.6% (n = 16) within a 36-month follow-up period (mean, 11.5 ± 12 months). Patients suffering from amyloidosis with additional proof of intramyocardial inflammation revealed significantly decreased survival (group 1, n = 26) compared to patients without intramyocardial inflammation (group 2, n = 28; Figure 2A , log-rank P = 0.019). A total of 12 out of 26 patients with myocardial inflammation died within 36 months (median survival 13.1 months), whereas only four out of 28 patients in the inflammation-negative group met the endpoint of death (contingency Fisher's exact test P = 0.016). The amyloid deposit area fraction did not differ significantly between patients with or without intramyocardial inflammation [Student's t-test P = 0.149, percent area fraction (AF) 42.19 ± 20.33/AF (group I + III) vs. 31.67 ± 22.89/AF (group II + IV)] nor among all four groups (group I to IV, ANOVA P = 0.157). Survival proportions regarding amyloid load of censored patients showed a poorer prognosis for AL amyloidosis in general but no influence of the amyloid load to survival (P = 0.27). Although the systemic biomarker levels were above the threshold in all four groups indicating cardiac involvement, there were no statistically different plasma concentrations of NT-proBNP (ANOVA P = 0.7) or troponin T (ANOVA P = 0.5) among the four groups nor between inflammation vs. no inflammation (Student's t-test P = 0.2 and P = 0.4, respectively) nor between AL and ATTR amyloidosis (Student's t-test P = 0.3 and P = 0.4, respectively). Left ventricular ejection fraction, LV end-diastolic diameter (LVEDD), and LV hypertrophy did not differ within the patients with and without inflammation on EMB nor in patients with AL or ATTR amyloidosis ( Table 1) .
A further differentiation of the inflammatory cells disclosed CD3
+ and LFA-1 + lymphocytes as predictive markers for a poorer outcome in amyloidosis (Kaplan-Meier log-rank P = 0.001 and P < 0.0001, respectively; Figure 2B ). Cytotoxic T cells, CD45R0 memory T cells, and macrophages had no significant predictive power for all-cause mortality in patients with amyloidosis (data not shown).
Re-grouping of patients according to their amyloidosis classes [ATTR = group A (n = 26) and AL = group B (n = 28)] showed a significant impact on all-cause mortality (Kaplan-Meier log-rank P = 0.012; Figure 2C ). Four out of 26 patients with ATTR amyloidosis compared to 12 out of 28 patients with AL amyloidosis (median survival 11.8 months) had died within 36 months (contingency Fisher's exact test P = 0.027).
An additional exploratory analysis revealed inflammation, amyloid type, and age at biopsy as influencing parameters for survival (see Supplementary material online, Table S1 ). The detailed subgroup analysis showed that patients suffering from AL amyloidosis with intramyocardial inflammation have a significantly worse prognosis in comparison to AL amyloidosis without inflammation and ATTR with or without inflammation, respectively ( Figure 2D , log-rank P = 0.014, contingency Fisher's exact test P = 0.008).
Discussion
Amyloidosis is a fatal disease with rapid deterioration after cardiac involvement occurs. 17 This study was intended to show the untreated natural course of the disease and the prognostic relevance of an exact and comprehensive histological and immunohistochemical examination of EMBs in these patients. For the first time, this report shows a high incidence (48.1%) of intramyocardial inflammation in a series of patients with EMB-proven cardiac amyloidosis. Additionally, in patients with cardiac AL amyloidosis, lymphocytic intramyocardial inflammation has a major contribution to increased mortality.
Previously, an interrelation between immune-mediated inflammation and systemic amyloid could be observed in mice. There, serum amyloid A increased up to 1000-fold after proinflammatory stimuli. The higher the inflammation occurred the more amyloid was built. 18 The overall cardiac damage is due to both tissue infiltration and direct toxicity of pre-amyloid proteins, in particular in . Moreover, in patients with AL but not ATTR amyloidosis, it has been reported that cardiac amyloid load could have influence due to toxic effects of light chains on cardiomyocytes. 19 However, in our analyses, not amyloid load but the combination of inflammation and AL amyloid showed a tremendous effect. In contrast, in patients with ATTR amyloidosis, intramyocardial inflammation did not affect the patient's prognosis, indicating a lower progression potential of this type of amyloidosis. 20 The prognostic value of troponin and NT-proBNP is controversial owing to diverse studies in inflammatory cardiac processes. Troponin has been found useful for the detection of myocardial necrosis in myocarditis and heart failure. 21, 22 However, in patients with fulminant acute myocarditis, low troponin values were related to worse cardiac output, lower LV ejection fraction on admission, and a greater incidence of hospital and mid-term outcomes. 23 In our patients suffering from AL or ATTR amyloidosis with or without myocardial inflammation, no statistical difference between the mean in each subgroup or a prognostic value could be seen for troponin and NT-proBNP, possibly due to the complexity in this particular case.
Only limited therapeutic options exist when cardiac amyloidosis has already occurred. In case of advanced cardiac AL amyloidosis Figure 2 Intramyocardial inflammation is associated with lower survival rates in patients with amyloidosis. Survival curves were generated according to the Kaplan-Meier method and were compared with the log-rank statistics. The overall mortality in our patient cohort (n = 16) was 29.6% over a 36-month follow-up period (mean 11.5 ± 12 months). (A) Patients suffering from amyloidosis with intramyocardial inflammation (group 1, red line, n = 26, median survival 13.1 months) significantly differ from those without intramyocardial inflammation (group 2, black line, n = 28); log-rank P = 0.019. (B) Patients (n = 54) suffering from amyloidosis disregarding the type but differentiating inflammatory cells show that only increased CD3
+ and LFA-1 + lymphocytes are predictive of poor prognosis (log-rank P = 0.001 and P < 0.0001, respectively). (C) Patients suffering from amyloidosis with ATTR amyloidosis (group A, red line, n = 26) significantly differ from those with AL amyloidosis (group B, black line, n = 28, median survival 11.8 months); log-rank P = 0.012. (D) Patients suffering from ATTR amyloidosis with intramyocardial inflammation (group I, red line, n = 10), without intramyocardial inflammation (group II, orange line, n = 16), and from AL amyloidosis without inflammation (group III, blue line, n = 16) significantly differ from those with AL amyloidosis and inflammation (group IV, black line, n = 12); log-rank P = 0.014. AL, amyloid light-chain amyloidosis; ATTR, amyloid transthyretin amyloidosis; LFA-1, lymphocyte function-associated antigen-1. in multiple myelomas, the proteasome inhibitor bortezomib prolonged the patient's survival compared to untreated individuals. 24 This effect is enhanced in combination with dexamethasone, underlying the hypothesis that an inflammatory process might play a crucial role in this disease. Recent clinical and experimental evidence has suggested that immune activation and the consequential inflammatory response in the myocardium may be involved in the process of deteriorating cardiac function. 25 Both pro-inflammatory and anti-inflammatory infiltrates were associated with poor prognosis in, for instance, dilated cardiomyopathy patients, leading to some profound pathophysiological implications regarding disease progression of cardiomyopathy. 26 Regardless of the trigger of myocardial inflammation, the subsequent immune activation accompanied by a persistence of myocardial inflammatory infiltrates may be a causative factor of the deterioration in severe heart failure. 27 The primary purpose of the inflammatory response aiming at adequate tissue repair or reparative remodelling will then have failed, and finally the need for specific immunosuppressive treatment arises. 28 -30 Therefore, we hypothesize that additional immunosuppressive therapy in patients with cardiac amyloidosis might be a meaningful therapeutic option in the future, and thereby immunosuppressive treatment would stop further inflammatory processes before immune-mediated myocyte injury and possible haemodynamic deterioration occur.
Some study limitations have to be acknowledged. First of all, the number of patients enrolled in this study is limited. The typical limitations of retrospective cohort studies apply to our analyses. These include, among other parameters, the lack of data of novel speckle tracking echocardiography, diastolic function data, cardiac imaging with magnetic resonance and 99mTc-phosphate scintigraphy, serum and urine immunofixation, and quantification of free serum light chains. Additionally, a limitation is the lack of discrimination between mutated and wild type ATTR. At the time point of the study, no included AL patient was treated specifically that strengthens the relevance of our data by excluding the influence of different therapy regimens, as it was not designed as a treatment study.
Taken together, our findings show for the first time that in patients with cardiac AL amyloidosis, lymphocytic myocardial inflammation correlates significantly with decreased survival. Our data have a direct clinical impact. For that, further large randomized studies are necessary to evaluate whether additional different immuno-modulating/anti-inflammatory treatment regimens in patients with EMB-proven inflammation of heart muscle tissue could be beneficial for patients suffering from cardiac AL amyloidosis. In contrast to other imaging techniques, the analysis of EMBs is not only necessary for proof of cardiac involvement of amyloidosis, but essential for amyloid typing and for proof of inflammation in the heart muscle in patients with amyloidosis to assess the prognosis and to allow possible adjustment of therapy.
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